MRC1 and cancer: Treatment with RP-182 peptide, which binds to CD206/mannose receptor 1 and induces a conformational switch of the receptor, partially depletes CD206+ macrophages and reprograms the remaining TAMs into antitumor M1-like effectors with increased inflammatory cytokine production and the ability to phagocytose cancer cells (6, 266).